Prevalence, Trends, and Distribution of Nicotine and Marijuana use in E-cigarettes among US adults: The Behavioral Risk Factor Surveillance System 2016-2018.

Journal Article (Journal Article)

Use of substances other than nicotine in e-cigarettes, especially marijuana, is becoming increasingly popular in the US. However, population-representative data on such poly-use (nicotine and marijuana) remains limited. We therefore conducted a cross-sectional logistic regression analysis of the 2018 Behavioral Risk Factor Surveillance System among 16 US states/territories with data on past 30-day marijuana use to describe the emerging dual nicotine and marijuana vaping population. We additionally examined trends in marijuana use, including marijuana vaping, from 2016 to 2018. Of the 131,807 participants studied, 3068 were current e-cigarette users, among whom 7.1% also vaped marijuana. Prevalence of nicotine-predominant, dual nicotine marijuana, and marijuana-predominant vaping was 3.36%, 0.38% and 1.09%, respectively. Compared to nicotine-predominant vapers, dual and marijuana-predominant vapers were older, had greater proportions of non-Whites, particularly Hispanics, and less likely to be current smokers (nicotine-predominant vs dual vs marijuana-predominant vaping: current tobacco use 44.7 vs 23.7 vs 11.1%). Proportion of dual vapers among current e-cigarette users was 8.6%, 2.6% and 7.1% for 2016, 2017 and 2018, respectively. Prevalence of marijuana use increased from 8.97% (2016) to 13.1% (2018) while no clear trend was observed for marijuana vaping. Dual nicotine and marijuana vaping is prevalent in the US, and compared to predominantly nicotine vapers such users have higher mean ages, and are more likely to be Blacks, Hispanics, and never cigarette smokers. Marijuana use overall increased from 2016 to 2018. Dual vapers represent a large and important emerging population that will require dedicated study of health effects and tailored regulatory strategies.

Full Text

Duke Authors

Cited Authors

  • Uddin, SMI; Osei, AD; Obisesan, OH; El-Shahawy, O; Dzaye, O; Cainzos-Achirica, M; Mirbolouk, M; Orimoloye, OA; Stokes, A; Benjamin, EJ; Bhatnagar, A; DeFilippis, AP; Henry, TS; Nasir, K; Blaha, MJ

Published Date

  • October 2020

Published In

Volume / Issue

  • 139 /

Start / End Page

  • 106175 -

PubMed ID

  • 32593733

Pubmed Central ID

  • PMC8383272

Electronic International Standard Serial Number (EISSN)

  • 1096-0260

Digital Object Identifier (DOI)

  • 10.1016/j.ypmed.2020.106175


  • eng

Conference Location

  • United States